Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability

Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant

 
• By Dean Rudge

In an exclusive interview, the executive vice-president for Samsung Bioepis’ commercial division, Sang-Jin Pak, tells Generics Bulletin there is plenty of opportunity remaining in the crammed US trastuzumab market and explains what an achievement it was for the South Korea-based company to reach profitability only eight years after inception.

Korea
Incheon-based Samsung Bioepis believes there is a 'good opportunity' in the US trastuzumab market • Source: Shutterstock

Samsung Bioepis is realistic about the challenges it faces in the packed-out trastuzumab market in the US but is sanguine that conditions exist for it to establish fair market share, especially with uptake and acceptance for biosimilars continuing to rise, the South Korea-based firm has told Generics Bulletin.

Speaking after commercialization partner Merck & Co made Ontruzant (trastuzumab-dttb) the fifth US biosimilar to Genentech’s Herceptin available in the space of just nine months, Samsung Bioepis’ executive vice-president for its commercial division, Sang-Jin Pak, intimated there was an upside to biosimilars flooding the market in this way

More from Biosimilars

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.